Sequoia Financial Advisors LLC Sells 21,898 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Sequoia Financial Advisors LLC has reduced its stake in Gilead Sciences by 33.7%, selling 21,898 shares and now holding 43,102 shares valued at approximately $4.78 million.
• Gilead Sciences reported quarterly earnings of $2.01 per share, exceeding analysts' expectations, and an increase in revenue to $7.08 billion, which is up 1.4% year-over-year.
• The company declared a quarterly dividend of $0.79 per share, resulting in an annualized dividend of $3.16 and a yield of 2.7%.

Sequoia Financial Advisors LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.7% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 43,102 shares of the biopharmaceutical company's stock after selling 21,898 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Gilead Sciences were worth $4,779,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Vest Financial LLC increased its holdings in Gilead Sciences by 39.3% during the 2nd quarter. Vest Financial LLC now owns 14,472 shares of the biopharmaceutical company's stock worth $1,605,000 after purchasing an additional 4,080 shares in the last quarter. Welch Group LLC boosted its position in Gilead Sciences by 29.1% during the 2nd quarter. Welch Group LLC now owns 3,883 shares of the biopharmaceutical company's stock worth $431,000 after acquiring an additional 876 shares during the last quarter. Cypress Capital Group boosted its position in Gilead Sciences by 1.1% during the 2nd quarter. Cypress Capital Group now owns 48,533 shares of the biopharmaceutical company's stock worth $5,381,000 after acquiring an additional 551 shares during the last quarter. Stephens Consulting LLC boosted its position in Gilead Sciences by 113.7% during the 2nd quarter. Stephens Consulting LLC now owns 3,058 shares of the biopharmaceutical company's stock worth $339,000 after acquiring an additional 1,627 shares during the last quarter. Finally, MOKAN Wealth Management Inc. boosted its position in Gilead Sciences by 18.9% during the 2nd quarter. MOKAN Wealth Management Inc. now owns 19,352 shares of the biopharmaceutical company's stock worth $2,146,000 after acquiring an additional 3,072 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Up 0.2%

NASDAQ GILD opened at $118.48 on Wednesday. The company has a market cap of $147.01 billion, a PE ratio of 23.60, a PEG ratio of 0.80 and a beta of 0.34. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $84.80 and a 12 month high of $121.83. The stock has a 50 day moving average of $114.84 and a 200-day moving average of $110.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter in the prior year, the business earned $2.01 EPS. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GILD. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and upped their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Cantor Fitzgerald upped their price target on Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Rothschild & Co Redburn upped their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. Citigroup increased their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a report on Wednesday, October 8th. Finally, UBS Group increased their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $118.08.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,000 shares of company stock worth $7,632,100. Company insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.